Suppr超能文献

标准胰十二指肠切除术、附加门静脉及多脏器切除术治疗胰头癌的围手术期及长期预后

Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer.

作者信息

Kulemann Birte, Hoeppner Jens, Wittel Uwe, Glatz Torben, Keck Tobias, Wellner Ulrich F, Bronsert Peter, Sick Olivia, Hopt Ulrich T, Makowiec Frank, Riediger Hartwig

机构信息

Department of Surgery, University of Freiburg, Hugstetter Str. 55, D-79106, Freiburg, Germany,

出版信息

J Gastrointest Surg. 2015 Mar;19(3):438-44. doi: 10.1007/s11605-014-2725-8. Epub 2015 Jan 8.

Abstract

INTRODUCTION

The value of extended resection (portal vein, multivisceral) in patients with pancreatic adenocarcinoma (PDAC) is not well defined. We analyzed the outcome after standard resection (standard pancreaticoduodenectomy (SPR)), additional portal vein (PV) and multivisceral (MV) resection in PDAC patients.

METHODS

Clinicopathologic, perioperative, and survival data of patients undergoing pancreatic head resection (PHR) for PDAC 1994-2014 were reviewed from a prospective database.

RESULTS

Three hundred fifty nine patients had PHR for PDAC: 208 (58 %) underwent SPR, 131 (36 %) additional PV, and 20 (6 %) MV. The postoperative complication rate in MV (65 %) was slightly higher than in PV (56 %) or SPR (50 %; p = 0.32). MV patients had higher in-hospital mortality (10 %) than SPR (3.8 %) and PV (1.5 %) patients (p = 0.12). Nodal status was comparable, whereas more patients in PV and MV had final R0 resection (p = 0.02). Five-year survival was 7 % after MV versus 17 % in patients without MV (p = 0.07). Multivariate survival analysis identified resection margin, nodal disease, blood transfusions, and MV are set as independent risk factors for overall survival.

CONCLUSION

Multivisceral pancreatic head resections for PDAC are associated with increased perioperative morbidity and mortality, without improving oncologic outcome. Portal vein resection can be performed safely to reach R0 resection and its survival benefits.

摘要

引言

在胰腺腺癌(PDAC)患者中,扩大切除术(门静脉、多脏器)的价值尚未明确界定。我们分析了胰腺腺癌患者行标准切除术(标准胰十二指肠切除术(SPR))、附加门静脉(PV)和多脏器(MV)切除术后的结局。

方法

回顾了1994 - 2014年因PDAC接受胰头切除术(PHR)患者的临床病理、围手术期和生存数据,这些数据来自一个前瞻性数据库。

结果

359例患者因PDAC接受了PHR:208例(58%)接受了SPR,131例(36%)接受了附加PV切除,20例(6%)接受了MV切除。MV组术后并发症发生率(65%)略高于PV组(56%)或SPR组(50%;p = 0.32)。MV组患者的院内死亡率(10%)高于SPR组(3.8%)和PV组(1.5%)患者(p = 0.12)。淋巴结状态相当,而PV组和MV组中更多患者实现了R0切除(p = 0.02)。MV组患者的5年生存率为7%,而未行MV切除的患者为17%(p = 0.07)。多因素生存分析确定切缘、淋巴结疾病、输血和MV切除为总生存的独立危险因素。

结论

PDAC患者行多脏器胰头切除术与围手术期发病率和死亡率增加相关,且未改善肿瘤学结局。门静脉切除可安全实施以实现R0切除及其生存获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验